title: Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
authors.affiliation: Department of Surgery, Virchow Clinics, Humbolt-University Berlin, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Klupp
authors.forename: W O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: J
authors.initials: J
authors.lastname: Pratschke
authors.forename: S G
authors.initials: SG
authors.lastname: Tullius
authors.forename: A
authors.initials: A
authors.lastname: Gebhard
authors.forename: H
authors.initials: H
authors.lastname: Lobeck
authors.forename: J M
authors.initials: JM
authors.lastname: Langrehr
authors.forename: R
authors.initials: R
authors.lastname: Neuhaus
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology* / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011239:Prednisolone; D001379:Azathioprine; D016559:Tacrolimus